Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Canopy Growth CorporationNASDAQ: CGC

Accounts Receivables · Q4 FY2025 · quarter ended Mar 2026

Accounts receivables turns positive

Q4 FY2025 accounts receivables was CA$6.08M, compared with -CA$1.32M a year earlier. Trailing-twelve-month accounts receivables was CA$23.54M. Over 3 fiscal years it compounded at +60.2% a year.

Context

  • Accounts receivables amounted to 5.3% of revenue in FY2025, up 3.6 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near CA$6.08M or moves back toward the trailing-twelve-month quarterly average of CA$5.88M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$6.08M+176.7% QoQ
Last fiscal yearMar 2026
CA$25.69M+672.7% YoY
LTMMar 2026
CA$23.54M+624.8% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+559.8%——
1 year+672.7%——
3-year CAGR+60.2%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

CAD · from the cash flow

Latest · FY2025
25.69M CAD
Year-over-year change
+672.7%
4-year CAGR
+12.3%

Accounts Receivables vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +624.8% is the 2nd highest of 7, against a peer median of -80.0%.
  • Accounts receivables amounts to 7.5% of revenue for CGC, versus a peer median of 3.0%.
CGC Competitors
Accounts Receivables for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$66.07M USD-304.9%+63.8%18.3%
CGCCanopy Growth CorporationLTM Mar 2026CA$23.54M CAD+624.8%+60.2%7.5%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$8.6M USD—-28.3%6.4%
ACBAurora Cannabis Inc.LTM Mar 2026CA$8.17M CAD-225.0%—2.6%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$6.81M USD+5438.2%+253.5%81.4%
DHDefinitive Healthcare Corp.LTM Mar 2026$4.29M USD-67.1%—1.8%
BIOABioAge Labs, Inc.LTM Mar 2026$348K USD-3.6%—3.4%
TKNOAlpha Teknova, Inc.LTM Mar 2026$86K USD-93.0%—0.2%
LYELLyell Immunopharma, Inc.LTM Mar 2026$0 USD——0.0%
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD———
Peer median (excluding CGC) —-80.0%+63.8%3.0%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Net Income(258.91M)(3.08B)(483.68M)(604.14M)(366.64M)
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
Deferred Income Tax(8.95M)(5.73M)12.33M7.14M0
Stock-Based Compensation46.69M25.32M14.18M(4.21M)5.95M
Change in Working Capital205M58.97M3.97M(31.97M)20.68M
Accounts Receivables16.15M6.24M(3.75M)(4.49M)25.69M
Inventory204.22M68.44M1.03M(17.72M)3.71M
Accounts Payables00000
Other Working Capital(15.37M)(15.71M)6.68M(9.77M)(8.72M)
Other Non-Cash Items(640.58M)2.36B118.08M424.3M200.17M
Operating Cash Flow(545.81M)(557.55M)(281.95M)(165.75M)(88.98M)
Capital Expenditures(48.11M)(10.45M)(4M)(11.28M)(7.44M)
Acquisitions (Net)103.2M14.93M(955K)(6.97M)0
Purchases of Investments(379.41M)(67.15M)(347K)(95.34M)0
Sales of Investments546.01M502.59M78.55M16.43M26.5M
Other Investing Activities(2.3M)(7.88M)167.79M48.9M(48.83M)
Investing Cash Flow230.82M433.38M241.59M(47.79M)(29.77M)
Debt Repayment(50.76M)16.98M(509.78M)(220.78M)(24.62M)
Common Stock Issued2.7M1.05M81.06M385.39M374.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.53M(37.72M)(36.34M)(15.96M)114.02M
Financing Cash Flow(45.53M)(19.69M)(465.06M)148.66M463.57M
Effect of Forex Changes(18.12M)44.86M(1.29M)8.39M5.05M
Net Change in Cash(378.65M)(99M)(506.71M)(56.49M)349.86M
Free Cash Flow(593.92M)(568M)(285.95M)(177.03M)(96.42M)

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.